PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Combination therapy - Market size and forecast 2018-2023 Monotherapy - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Advent of novel therapies Research grants and funding Special drug designations PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Allergan Plc AstraZeneca Plc Celgene Corp. Johnson & Johnson Services Inc. Takeda Pharmaceutical Co. Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017 Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Pipeline molecules Exhibit 44: Growth in geriatric population 2013-2017 (%) Exhibit 45: Side effects of drugs treating mantle cell lymphoma Exhibit 46: Impact of drivers and challenges Exhibit 47: Drug designations Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: Allergan Plc - Vendor overview Exhibit 55: Allergan Plc - Business segments Exhibit 56: Allergan Plc - Organizational developments Exhibit 57: Allergan Plc - Geographic focus Exhibit 58: Allergan Plc - Segment focus Exhibit 59: Allergan Plc - Key offerings Exhibit 60: Allergan Plc - Key customers Exhibit 61: AstraZeneca Plc - Vendor overview Exhibit 62: AstraZeneca Plc - Product segments Exhibit 63: AstraZeneca Plc - Organizational developments Exhibit 64: AstraZeneca Plc - Geographic focus Exhibit 65: AstraZeneca Plc - Key offerings Exhibit 66: AstraZeneca Plc - Key customers Exhibit 67: Celgene Corp. - Vendor overview Exhibit 68: Celgene Corp. - Business segments Exhibit 69: Celgene Corp. - Organizational developments Exhibit 70: Celgene Corp. - Geographic focus Exhibit 71: Celgene Corp. - Key offerings Exhibit 72: Celgene Corp. - Key customers Exhibit 73: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 74: Johnson & Johnson Services, Inc. - Business segments Exhibit 75: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 76: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 77: Johnson & Johnson Services, Inc. - Segment focus Exhibit 78: Johnson & Johnson Services, Inc. - Key offerings Exhibit 79: Johnson & Johnson Services, Inc. - Key customers Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors

Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.